Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:35:12 EDT Thu 18 Jun 2026
Enter Symbol
or Name
USA
CA



Q:IBIO - IBIO INC - https://www.ibioinc.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IBIO - Q7.31.34·1.690.61.60+0.053.21,671.22,3354,1831.57  1.63  1.483.82  0.556219:04:12Jun 0215 min RT 2¢

Recent Trades - Last 10 of 4183
Time ETExPriceChangeVolume
19:04:12Q1.59850.048522
18:05:16Q1.54-0.011
16:58:53Q1.55370.00373
16:23:42Q1.54-0.012,000
16:21:51Q1.5317-0.01832
16:13:51Q1.60170.051740
16:10:05Q1.600.051
16:10:05Q1.600.051
16:10:04Q1.600.051
16:10:04Q1.600.051

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-06-02 16:01U:IBIONews ReleaseiBio to Participate in Upcoming Healthcare Investor Conferences
2026-06-02 07:00U:IBIONews ReleaseiBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
2026-05-12 16:05U:IBIONews ReleaseiBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-05-08 07:15U:IBIONews ReleaseiBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
2026-04-08 07:00U:IBIONews ReleaseiBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
2026-03-16 16:30U:IBIONews ReleaseiBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
2026-03-09 07:00U:IBIONews ReleaseiBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
2026-02-24 07:00U:IBIONews ReleaseiBio to Participate in Upcoming Investor Conferences
2026-02-10 16:05U:IBIONews ReleaseiBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-01-09 07:00U:IBIONews ReleaseiBio Announces $26 Million Private Placement
2025-11-24 16:15U:IBIONews ReleaseiBio to Participate in the 8th Annual Evercore Healthcare Conference
2025-11-12 16:01U:IBIONews ReleaseiBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
2025-10-30 07:00U:IBIONews ReleaseiBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
2025-10-23 07:00U:IBIONews ReleaseiBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
2025-10-21 07:00U:IBIONews ReleaseiBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek(TM) and PEGS Europe 2025
2025-09-05 07:30U:IBIONews ReleaseiBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
2025-08-25 07:00U:IBIONews ReleaseiBio Announces Closing of $50 Million Public Offering
2025-08-19 08:01U:IBIONews ReleaseiBio Announces Pricing of $50 Million Public Offering
2025-08-18 16:01U:IBIONews ReleaseiBio Announces Proposed Public Offering
2025-06-24 07:00U:IBIONews ReleaseiBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results